Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：3
|
作者：
Piotrowska, Zofia [1 ]
Sequist, Lecia V. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期
关键词：
ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;
D O I：
10.1016/j.jtho.2017.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：419 / 421
页数：3
相关论文
共 50 条
  • [31] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Nebhan, Caroline A.
    Pirazzoli, Valentina
    Wang, Lu
    Lu, Pengcheng
    Vuong, Huy
    Hutchinson, Katherine E.
    Jia, Peilin
    Chen, Xi
    Eisenberg, Rosana
    Ladanyi, Marc
    Politi, Katerina
    Zhao, Zhongming
    Lovly, Christine M.
    Cross, Darren A. E.
    Pao, William
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
  • [32] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
    Zhang, Yidan
    Xu, Yingqi
    Xu, Jianlin
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    CANCER SCIENCE, 2024, : 753 - 763
  • [33] A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
    Liu, Li
    Qu, Jingjing
    Heng, Jianfu
    Zhou, Chunhua
    Xiong, Yi
    Yang, Haiyan
    Jiang, Wenjuan
    Zeng, Liang
    Zhu, Songlin
    Zhang, Yongchang
    Tan, Jiarong
    Hu, Chengping
    Deng, Pengbo
    Yang, Nong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
    Lim, Jeong Uk
    Jung, Junyang
    Kim, Yeon Wook
    Kim, Chi Young
    Lee, Sang Hoon
    Park, Dong Won
    Choi, Sue In
    Ji, Wonjun
    Yeo, Chang Dong
    Lee, Seung Hyeun
    BIOMEDICINES, 2025, 13 (02)
  • [35] A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
    Rivera-Concepcion, Joel
    Lo, Ying-Chun
    Uprety, Dipesh
    Adjei, Alex A.
    Ernani, Vinicius
    Leventakos, Konstantinos
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2024, 13
  • [36] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
    Zhang, Zhe
    Yang, Sen
    Wang, Qiming
    BIOMARKER RESEARCH, 2019, 7 (01)
  • [37] Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
    Cao, Fei
    Gong, Ya-Bin
    Kang, Xiao-Hong
    Lu, Zhi-Hong
    Wang, Ying
    Zhao, Ke-Lei
    Miao, Zhan-Hui
    Liao, Ming-Juan
    Xu, Zhen-Ye
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 379
  • [38] Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer
    Lee, Youngjoo
    Lee, Geon Kook
    Hwang, Jung-Ah
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    CLINICAL LUNG CANCER, 2015, 16 (01) : 46 - 50
  • [39] Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment
    Del Re, Marzia
    Addeo, Alfredo
    Passaro, Antonio
    Petrini, Iacopo
    van Schaik, Ron H. N.
    Danesi, Romano
    PHARMACOGENOMICS, 2019, 20 (18) : 1255 - 1257
  • [40] Association between EGFR-TKI Resistance and Efficacy of Radiotherapy for Brain Metastases from EGFR-mutant Lung Adenocarcinoma
    Hirata, Hidenari
    Nakamura, Katsumasa
    Kunitake, Naonobu
    Shioyama, Yoshiyuki
    Sasaki, Tomonari
    Ohga, Saiji
    Nonoshita, Takeshi
    Yoshitake, Tadamasa
    Asai, Kaori
    Inoue, Kouji
    Nagashima, Akira
    Ono, Minoru
    Honda, Hiroshi
    ANTICANCER RESEARCH, 2013, 33 (04) : 1649 - 1655
12345